Dr. Gwen Canarias Fuentes, M.D. Pediatrics Medicare: Not Enrolled in Medicare Practice Location: 919 15th Ave Nw, Ardmore, OK 73401 Phone: 580-223-5693 Fax: 580-223-8909 |
Lisa Christine Hoffman, MD Pediatrics Medicare: Medicare Enrolled Practice Location: 1020 N Commerce St, Ardmore, OK 73401 Phone: 580-223-5311 Fax: 580-223-2397 |
Derek Todd Landis, MD Pediatrics Medicare: Accepting Medicare Assignments Practice Location: 921 14th Ave Nw, Ardmore, OK 73401 Phone: 580-223-5311 Fax: 580-223-8227 |
Miguel Antonio Camacho-garrido, MD Pediatrics - Adolescent Medicine Medicare: Not Enrolled in Medicare Practice Location: 1104 Walnut Dr, Ardmore, OK 73401 Phone: 580-226-0543 Fax: 580-226-2284 |
News Archive
3M and MicroDose Technologies Inc., a privately held drug delivery company based in Monmouth Junction, N.J., announced today that the two companies have entered into an exclusive co-development and joint marketing agreement.
A study examining the incidence of peripartum cardiomyopathy in women who gave birth at a Medical College of Georgia's teaching hospital between July 2003 and July 2008, showed that while 55 percent of the women were white, 93 percent of those who developed cardiomyopathy were black, said Dr. Mindy B. Gentry, an MCG cardiologist.
In a Nursing Open study, peer relations and self-rated health were associated with smoking behavior in both girls and boys studying in upper secondary vocational schools.
Alere Inc., a global leader in rapid diagnostics announced today the completion of the previously announced sale of its BBI business to Exponent Private Equity LLP, a UK-based private equity firm. BBI Group provides products and services for the diagnostic, healthcare, research, defense and food industries globally.
NicOx S.A. today announced that the European Medicines Agency (EMEA) has validated the Marketing Authorization Application (MAA) for naproxcinod, which was submitted through the centralized procedure in December 2009. NicOx is seeking approval for an indication for the relief of the signs and symptoms of primary osteoarthritis. This follows the acceptance for filing of a New Drug Application (NDA) by the US Food and Drug Administration (FDA) in November 2009.
› Verified 4 days ago